Lisata Therapeutics (LSTA) Competitors

Lisata Therapeutics logo
$0.90 -0.01 (-1.22%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.88 -0.02 (-2.44%)
As of 11/20/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LSTA vs. MREO, PLRX, ELTX, YARW, and ALPS

Should you buy Lisata Therapeutics stock or one of its competitors? Lisata Therapeutics's main competitors and comparable companies include Mereo BioPharma Group (MREO), Pliant Therapeutics (PLRX), Elicio Therapeutics (ELTX), Yarrow Bioscience (YARW), and ALPS Group Inc Ordinary Share (ALPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lisata Therapeutics compare to Mereo BioPharma Group?

Lisata Therapeutics (NASDAQ:LSTA) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Lisata Therapeutics has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K57.11-$16.59M-$1.88N/A
Mereo BioPharma Group$500K83.04-$41.88M-$0.04N/A

Mereo BioPharma Group's return on equity of -84.62% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -167.79% -9.93%
Mereo BioPharma Group N/A -84.62%-71.44%

Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

In the previous week, Lisata Therapeutics had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Lisata Therapeutics and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.00 beat Lisata Therapeutics' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company Overall Sentiment
Lisata Therapeutics Neutral
Mereo BioPharma Group Neutral

Mereo BioPharma Group has a consensus target price of $1.67, indicating a potential upside of 541.03%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Mereo BioPharma Group
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 8.4% of Lisata Therapeutics shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Mereo BioPharma Group beats Lisata Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Lisata Therapeutics has higher revenue and earnings than Pliant Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant TherapeuticsN/AN/A-$149.34M-$1.45N/A
Lisata Therapeutics$170K57.11-$16.59M-$1.88N/A

Pliant Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 404.12%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Pliant Therapeutics' return on equity of -57.13% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pliant TherapeuticsN/A -57.13% -44.97%
Lisata Therapeutics N/A -167.79%-9.93%

In the previous week, Lisata Therapeutics had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.00 beat Lisata Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pliant Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lisata Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pliant Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Summary

Pliant Therapeutics beats Lisata Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Elicio Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Lisata Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

Elicio Therapeutics has a consensus target price of $15.00, indicating a potential upside of 934.48%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Elicio Therapeutics is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 8.4% of Lisata Therapeutics shares are held by company insiders. Comparatively, 34.6% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Lisata Therapeutics had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for Lisata Therapeutics and 0 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 0.00 beat Lisata Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Lisata Therapeutics Neutral
Elicio Therapeutics Neutral

Lisata Therapeutics' return on equity of -167.79% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -167.79% -9.93%
Elicio Therapeutics N/A -529.69%-119.64%

Lisata Therapeutics has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K57.11-$16.59M-$1.88N/A
Elicio TherapeuticsN/AN/A-$39.57M-$1.87N/A

Summary

Elicio Therapeutics beats Lisata Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Yarrow Bioscience?

Lisata Therapeutics (NASDAQ:LSTA) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are owned by institutional investors. 8.4% of Lisata Therapeutics shares are owned by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lisata Therapeutics has higher earnings, but lower revenue than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K57.11-$16.59M-$1.88N/A
Yarrow Bioscience$570K344.68-$26.48M-$14.64N/A

Yarrow Bioscience has a consensus target price of $52.67, indicating a potential upside of 308.27%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Yarrow Bioscience
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 3 articles in the media. Yarrow Bioscience's average media sentiment score of 0.53 beat Lisata Therapeutics' score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lisata Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Yarrow Bioscience
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

Lisata Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -28.99% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -167.79% -9.93%
Yarrow Bioscience -4,726.21%-28.99%-28.03%

Summary

Yarrow Bioscience beats Lisata Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to ALPS Group Inc Ordinary Share?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Lisata Therapeutics had 2 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 0.00 beat Lisata Therapeutics' score of 0.00 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lisata Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
Lisata Therapeutics N/A -167.79%-9.93%

27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 25.5% of ALPS Group Inc Ordinary Share shares are held by insiders. Comparatively, 8.4% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ALPS Group Inc Ordinary Share has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M7.50-$2.01M$1.300.88
Lisata Therapeutics$170K57.11-$16.59M-$1.88N/A

ALPS Group Inc Ordinary Share has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

ALPS Group Inc Ordinary Share beats Lisata Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LSTA vs. The Competition

MetricLisata TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.71M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.60%
P/E Ratio-0.4823.0732.5628.68
Price / Sales97.1214.847.815.19
Price / CashN/A21.9220.2520.77
Price / Book1.274.124.343.51
Net Income-$16.59M-$24.08M$3.51B$394.12M
7 Day Performance-25.71%-9.85%-8.07%-8.97%
1 Month Performance-10.56%-12.77%-10.29%-11.61%
1 Year Performance-54.14%-7.99%-4.70%-11.21%

Lisata Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LSTA
Lisata Therapeutics
0.3399 of 5 stars
$0.90
-1.2%
N/A-54.1%$9.71M$100KN/A21
MREO
Mereo BioPharma Group
1.8411 of 5 stars
$0.29
+5.4%
$1.67
+476.1%
-85.6%$43.83M$500KN/A39
PLRX
Pliant Therapeutics
1.2186 of 5 stars
$0.66
+0.1%
$3.00
+353.9%
-61.6%$40.93M$1.58MN/A49
ELTX
Elicio Therapeutics
1.6407 of 5 stars
$1.59
+11.2%
$15.00
+843.4%
-81.9%$40.48MN/AN/A33
YARW
Yarrow Bioscience
2.4149 of 5 stars
$14.35
+1.0%
$52.67
+267.0%
N/A$37.94M$570KN/A30

Related Companies and Tools


This page (NASDAQ:LSTA) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners